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Continuous application of transdermal nitroglycerin ap-
pears to result in tolerance to the antianginal effect. In
a double-blind study the effects of continuous (Z4 h/day)
and intermittent (16 h/day) application of transdermal
nitroglycerin in a dosage of 10 mg/day were compared
with the effects of placebo in 12 patients with chronic
stable angina receiving treatment with beta-adrenergic
blocking or calcium channel blocking agents. Exercise
performance was assessed 2 to 4 hours after initial ap-
plication and after 1 week of each treatment given in
random order with a 3 day interval between treatments.
Transdermal nitroglycerin is currently widely used in the
treatment of angina pectoris. This method of nitrate admin-
istration is convenient for patients and can provideconstant
serum drug levels ( 1). However there is increasing evidence
that sustained administration of nitrates can produce toler-
ance (2- 4). Several studies (5-9) with transdermal nitro-
glycerin have failed to show persisting therapeutic effect
despite demonstrable benefit during the first few hours of
treatment. That the therapeutic effect of transdermal nitro-
glycerin might be maintained using intermittent application
with a daily nitrate-free interval is suggested by the long-
term efficacy of short-acting nitrates. Thus. this study was
designed to compare the effects of continuous and inter-
mittentadministration of transdermal nitroglycerin with pla-
cebo. The effects of treatment were evaluated with exercise
testing in a group of patients with chronic stable angina but
relatively severe coronary artery disease who continued to
receive other antianginal medications.
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Exercise time to onset of angina, total exercise du-
ration and time to 1 mm ST segment depression were
all significantly increased after initial application during
the continuousand intermittent treatment periods. These
increases were maintained after 1 week of intermittent
but not continuous treatment. Thus the benefit of initial
application of transdermal nitroglycerin is maintained
with intermittent treatment and a daily nitrate-free in-
terval, whereas tolerance to antianginal effect occurs
with continuous treatment.
(J Am Coil CardioI1987,'lO:642-6)
Methods
Study patients (Table 1). The study group comprised
12 men, aged 38 to 70 years (mean 58), with chronic stable
angina pectoris, who had a positive treadmill exercise test
for ischemiaand whoseangina was responsive to sublingual
nitroglycerin. Six patients had had previous myocardial in-
farction. Eleven patients had undergone coronary angiog-
raphy; 10had significant three vessel disease and I had two
vessel disease. Elevenpatientswere takinga beta-adrenergic
blocking agent; five of these were also taking a calcium
channel blocker, and one patient was taking a calciumchan-
nel blocker only. Patients with myocardial infarction within
the previous 3 months, unstable angina, significant hyper-
tension (systolic blood pressure > 160 mm Hg or diastolic
blood pressure > 100 mm Hg), valvular heart disease, heart
failure or electrocardiographic (ECG) abnormalities pre-
cluding interpretation of exercise-induced ST segment changes
were not considered for the study.
Study design. The study period consisted of a control
week followed by three treatment periods, each of I week's
duration, chosen in random order in a Latin square design.
The treatment periods were separated by a washout period
of 3 days before crossover. During the treatment periods,
active and placebo transdermal systems were applied in a
double-blind fashion such that continuous. intermittent or
placebo treatment was provided. Patients applied a trans-
dermal system to the anterior chest wall on first awakening
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Table I. Clinical Data in 12 Patients
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Duration of Treatment
Patient Age Previous Angina
No. (yr) MI (yr) Coronary Angiography Beta-Blocker Calcium Channel Blocker
I 51 I Three VD +
2 60 5.5 Three VD + +
3 63 0.5 Three VD +
4 60 lUI Two VD + +
5 55 16 Three VD + +
6 38 + 2.5 Three VD + +
7 67 + 14 Three VD +
8 58 + 4 Three VD +
9 52 0.5 Three VD +
10 70 + 2 Three VD + +
II 57 + II Three VD +
12 63 + 18 +
MI = myocardial infarction; VD = vessel disease; - = no; + = yes.
in the morning and replaced it each night on retiring. An
active dose of 10 mg/day (20 cm/) (Nitroderm TTS Ciba)
was given to all patients. If intolerable side effects occurred.
the dose was halved for the remainder of the study. During
the continuous treatment period, the active system was re-
placed with a similar system on retiring, thus administering
transdermal nitroglycerin 24 hours each day. For intermit-
tent treatment, the active system was replaced with an iden-
tical placebo system allowing a nitrate-free interval of ap-
proximately 8 hours overnight. For placebo treatment, placebo
systems were applied during the day and night. All long-
acting nitrates were discontinued beforeentry into the study.
but other medications including beta-blockers and calcium
channel blockers were continued unchanged throughout the
study period.
Exercise testing. A bicycle exercise protocol was de-
vised for each patient during preliminary assessment, at
which time the patient was familiarized with the exercise
procedure (10). A Bosch bicycle ergometric system (ERG
551) was used with an integrated programmer and a speed-
independent constant loading system. An initial load of 40
W was applied with 20 W increments at 3 minute intervals.
The initial load was adjusted to 20 or 60 W if necessary to
ensure the onset of angina within 3 to 9 minutes of the start
of exercise. Patients developing angina within 3 minutes at
Table 2. Exercise Testing Results in 11 Patients
the lowest starting load (20 W) and those asymptomatic
after 9 minutes with the highest starting load (60 W) were
excluded.
For each subsequent exercise assessment during the con-
trol and treatment periods, duplicate tests were performed
separated by a rest interval of 30 minutes. For inclusion in
the trial. < 15% variation in the time to symptomatic end
points was required for the control tests. If later during the
treatment phase there was> 15%variation in duplicate tests,
a third test was undertaken after a further rest period. End
points were then averaged for two or three tests.
Exercise tests were performed at the end of the control
week and at the beginning (day I) and end (day 8) of the
three treatment weeks between 2 and 4 hours after morning
application of the transdermal system. A 12 lead ECG mon-
itoring system was used with recording of leads II. III. avF,
V2 • V4 • and Vh at 15 second intervals. Blood pressure was
measured at 3 minute intervals and at onset of angina using
an automated system.
Exercise end points were: I) time to onset of angina; 2)
total exercise duration (the stage at which the patient would
normally cease exertion); 3) time to I mm ST segment
depression (taken from the lead showing earliest ST segment
depression); and 4) heart rate-systolic blood pressure prod-
uct at onset of angina.
Placebo Continuous Intermittent
Control Initial I Week Initial I Week Initial I Week
Time to onset (s) 348 :t: 80 374 :t: 108 365 ± 103 446 ± 146* 362 ± 101 459 :t 125* 429 ± 12St
Exercise duration (s) 410 ± 76 442 :t 105 420 :t: 99 491 :t: 130* 419 ± 101 515 ± 122* 489±115t
Time to I mm ST depression (s) 332 ± 66 350 :t 109 331 :t: 83 437 :t 120* 345 ± 98 465 ± 1I4t 426 :t 95:1:
Rate-pressure product (beats/min x mm HgIlOO) 136 :t: 33 131 ± 27 138 ± 37 145 :t: 26* 137 ± 29 151 :t: 33* 147 ± 43
Values are mean ± SD; *p < 0.05; tp < 0.01; +P < 0.001 versus placebo.
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Figure I. Time to onset of angina (A)
and total exerciseduration(B) for con-
trol, placebo, continuous (Cont) and
intermittent (lnt) transdermal nitro-
glycerin treatment periods in II pa-
tients. Exercise results were similar for
control and placebo periods but were
significantly increased after initial ap-
plication (In) of both continuous and
intermittent treatments and after 1week
( Iwk) of intermittent treatment. Val-
ues are mean values ± SO; * p <
0.05, t p < 0.01 versus placebo.
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A diary record of angina frequ ency and sublingual ni-
troglycerin consumption was kept by all patients during the
control and treatment periods.
Statistical analysis. Group data were compared using
the paired Student 's t test. A probability (p) value of < 0 .05
was considered statistically significant.
Results
Eleven patients completed the study, one being with-
drawn because of an intercurrent illness during treatment.
No period or order effect was evident on data analysis.
Group data from the control and treatment periods are sum-
marized in Table 2 and Figure I. Total exercise duration
for individual patients is shown in Table 3.
Exercise test results. Exercise results were similar for
control and placebo treatment periods. After initial trans-
dermal system application on day I of the continuous and
intermittent treatment period s, time to onset of angina, total
exercise duration, time to I mm ST depression and rate-
pressure product at onset of angina were all significantly
increased compared with values during administration of
placebo . However, after I week of continuous treatment
there was no significant difference compared with placebo .
In contrast, time to onset of angina, exercise duration and
time to ST depression remained significantl y increased after
I week of intermittent treatment.
Angina frequency. There was no significant difference
in angina frequenc y or sublingual nitroglycerin consumption
between the continuous or the intermittent treatment per iod
and the placebo period.
Adverse effects. Three patient s experienced severe
headache during treatment but were able to complete the
study after reduct ion of transdermal nitroglycerin dosage to
5 mg/day. Another patient exper ienced tolerable mild head-
ache during treatment and dosage alteration was not re-
quired. No significant local skin reactions occurred.
Discussion
In this study we have shown that the anti anginal effect
of transdermal nitroglycerin demon strable after initial ap-
plication is maintained with intermittent application and a
Table 3. Total Exercise Duration (s) for II Individual Patients
Patient
Placebo Continuous lntermittent
No . Control Initial I Week Initial I Week Initial I Week
I 475 447 468 582 442 592 595
2 528 599 594 603 525 601 623
3 361 445 432 506 452 376 547
4 487 603 528 628 505 663 614
5 442 340 348 341 340 491 388
6 357 392 442 598 433 526 355
7 403 398 340 333 306 424 403
8 408 394 471 562 486 635 608
9 453 578 437 596 554 654 534
10 309 312 298 309 261 363 378
11 481 Withdrawn
12 286 356 265 341 280 343 340
Mean (± SD) 410 ± 76 442 ± 105 420 ± 99 491 ± 130 419 ± 101 515 ± 122 489 ± 115
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daily nitrate-free interval, whereas tolerance occurs with
continuous application.
Limitations of the stud y. The patients studied had rel-
atively severe coronary artery disease and it was not con-
sidered appropriate to withhold concomitant medication in
this group during the study period. Although such concom-
itant medication. and calcium channel blockers in particular.
might have infl uenced the response to treatment. results in
the six patients taking a calcium channel blucker were sim-
ilar to those in the other five patients. The limitations of
exercise testing in assessing patients with angina pectoris
are widely acknowledged. However, patients were carefully
selected for the study, the exercise protocol was indivi-
dualized and repeated exercise testing was applied to reduce
variability with serial evaluation. With this method of as-
sessment. a treatment effect was demonstrated after initial
application and this effect was maintained with intermittent
but not with continuous treatment. Nevertheless, exercise
testing at a single time interval after treatment application
does not allow one to conclude that. after intermittent treat-
ment. exercise tolerance is comparable throughout the day.
Time-dependent depression of antianginal effect may have
been evident if testing was performed at different time points
after application. and this remains a limitation of our study.
The slight variability in the timing of exercise testing (be-
tween 2 and 4 hours after treatment application) is a poten-
tially confounding factor. However. the time interval did
not vary for individual patients and there was no relation
betweenthe duration of the interval to testing and the amount
of change between the beginning and end of active treatment
periods among patients.
Tolerance to transdermal nitroglycerin. Several con-
trolled studies have demonstrated rapid attenuation of the
therapeutic effect of transdermal nitroglycerin. Reichek et
a!. (5) titrated nitroglycerin dosage to lower sitting blood
pressure by 10 mm Hg or to increase heart rate by 10
beats/min. With a mean dose of 9.4 mg/day, there was no
significant improvement over placebo in exercise perform-
ance at 4 or 24 hours. However. in a second limb of the
same study. maximal tolerated doses (mean duse 25 rng/day)
improved exercise tolerance at 4 and 8 hours but not at 24
hours. Response to sublingual nitroglycerin was maintained.
suggesting that tolerance was not complete and could be
overcome by an increase in plasma nitroglycerin levels.
Parker and Fung (6), using doses of 5 to 15 rug/day. showed
improvement in exercise time 4 hours after application but
no benefit after 24 hours. With continuous therapy for I to
2 weeks at a dose of 10 to 15 mg/day, there was no advantage
over placebo at either 4 or 24 hours after reapplication.
Other similar studies (8,9) have demonstrated lack of effect
after sustained therapy at doses up to 20 mg/24 h.
Conflic ting data come from the study of Thompson ( II )
in which a transdermal nitroglycerin dose of 10to 20 mg/day
significantly improved exercise performance at 2 and 26
hours after application. This result was achieved even though
some patients had a 10 day titration period before definitive
exercise testing. Scardi et a!. (12) also recorded a positive
experience showing that a dose of 10 or 20 mg/day improved
exercise capacity at 4 and 24 hours after application. How-
ever, considerable attenuation of therapeutic effect had oc-
curred by 24 hours.
Dosage and mechanisms of tolerance. Although we
used a relatively low. fixed nitroglycerin dose of 10 rug/day,
it was not tolerated in three cases. It is possible that con-
tinuous treatment may be more effective with higher doses.
Parker and Fung (6) assessed the effect of a high dose of
45 rug/day . Exercise time was prolonged at 2 and 4 hours
compared with placebo and. although still signifi cantly pro-
longed at 24 hours, it was clearly attenuated. Although the
mechanism of tolerance is not fully understood, it may relate
to depletion of sulfhydryl groups that mediate relaxation of
smooth muscle by nitroglycerin (13,14). Thus, higher dos-
age may not necessarily overcome tolerance and. indeed.
higher dosage for more prolonged periods might theoreti-
cally produce more complete tolerance requiring a longer
nitrate-free interval to reestablish therapeutic effect. Al-
though repletion of sulfhydryl groups may prevent tolerance
(15), the alternative provision of a nitrate-free interval ap-
pears more practicable.
Implications. Although we have shown that a nitrate-
free interval of approximately 8 hours allows maintenance
of therapeutic effect of transdermal nitroglycerin. further
studies are required to more accurately define the minimal
nitrate-free interval required. Most patients require antian-
ginal effect during the active waking hours. and overnight
removal and morning reapplication of transdermal systems
is convenient. However, it will be necessary to consider the
optimal timing of the nitrate-free interval during the 24 hour
period and. possibly, in some cases the necessity of pro-
viding alternative protection from ischemia during this time.
We acknowledge the expert secretarial assistance of Robyn Cliffe.
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